ATLAS News · Earnings

Moderna Returns to Quarterly Profit and Raises 2026 Revenue Growth Outlook

Published November 10, 2026 · 4 sources

Moderna posted Q3 2026 net income of $162 million and lifted its 2026 revenue growth forecast to 15%, ad-hoc-news.de reports.

What happened

Moderna returned to a quarterly profit and raised its revenue outlook for 2026, according to ad-hoc-news.de. The report ties the stock's recent attention to those two developments.

Ad-hoc-news.de says the company posted net income of $162 million for the third quarter of 2026 and lifted its 2026 revenue growth forecast to 15%. Another piece from the same outlet describes the raised guidance as facing its first real test on November 12.

A further ad-hoc-news.de article notes that the profit is real but arrives in only one quarter out of four. Separately, MLQ.ai reports that Baillie Gifford's third-quarter 13F filing shows Moderna and SpaceX trimmed, while chip-equipment makers were bought.

Context

Moderna is a vaccine-focused biotechnology company, and its results can vary from quarter to quarter.

Why it matters

The profit and higher guidance may shape how investors assess Moderna's earnings path, though the sources also point to uneven quarterly results.

Stocks in this story

Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.

ModernaMRNA

−6.75%

Healthcare · NASDAQ

Live price

$224.20▼ -6.75%

live price · USD

Close on November 10: $250.83−6.75% vs. previous close ($269.00)
Chance of a rise in 1 month: 44%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $178.67 and $258.59; 9 in 10, between $128.74 and $358.87.

See the full ATLAS analysis of Moderna →

Closing prices, fair value and probabilities: ATLAS own data. How we calculate fair value.

Sources

ATLAS writes its own summaries from the reporting of these outlets. Each link opens the original publisher.

Moderna stock weighs profit return against higher 2026 outlook · ad-hoc-news.de · November 10, 2026
Moderna's Raised Guidance Faces Its First Real Test on November 12 · ad-hoc-news.de · November 10, 2026
Baillie Gifford's third-quarter 13F: SpaceX and Moderna trimmed, chip-equipment makers bought · MLQ.ai · November 10, 2026
Moderna's Profit Is Real — But It Arrives in One Quarter Out of Four · ad-hoc-news.de · November 11, 2026

Latest market news · Markets today on ATLAS · Moderna

What you get with ATLAS

Create my ATLAS account →

Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.

Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer